Sakar Healthcare (NSEI:SAKAR) - Prezzo delle azioni, notizie e analisi

SAKAR Panoramica delle azioni

Sakar Healthcare Limited ricerca, sviluppa, produce e commercializza prodotti farmaceutici in India.

SAKAR analisi fondamentale
Punteggio fiocco di neve
Valutazione	0/6
Crescita futura	0/6
Prestazioni passate	2/6
Salute finanziaria	5/6
Dividendi	0/6

Premi

Analisi del rischio

Does not have a meaningful market cap (₹7B)

Shareholders have been diluted in the past year

Sakar Healthcare Limited Concorrenti

Ind-Swift Laboratories

NSEI:INDSWFTLAB

₹6.9b

Medicamen Biotech

BSE:531146

₹6.8b

Albert David

BSE:524075

₹8.0b

Wanbury

BSE:524212

₹7.6b

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Sakar Healthcare
Prezzi storici delle azioni
Prezzo attuale dell'azione	₹309.00
Massimo di 52 settimane	₹479.00
Minimo di 52 settimane	₹295.15
Beta	0.39
1Variazione di 1 mese	-3.18%
Variazione a 3 mesi	0.91%
Variazione di 1 anno	-16.88%
3Variazione a 3 anni	102.42%
Variazione a 5 anni	504.70%
Variazione dall'IPO	504.70%

Notizie e aggiornamenti recenti

Sakar Healthcare's (NSE:SAKAR) Anemic Earnings Might Be Worse Than You Think

Oct 30

Recent updates

Here's Why I Think Sakar Healthcare (NSE:SAKAR) Might Deserve Your Attention Today

Mar 23

Insider Buying: The Sakar Healthcare Limited (NSE:SAKAR) Chairman & MD Just Bought 7.1% More Shares

Mar 02

Has Sakar Healthcare Limited's (NSE:SAKAR) Impressive Stock Performance Got Anything to Do With Its Fundamentals?

Feb 08

Does Sakar Healthcare (NSE:SAKAR) Have A Healthy Balance Sheet?

Jan 10

Here's Why I Think Sakar Healthcare (NSE:SAKAR) Is An Interesting Stock

Dec 14

Should You Rely On Sakar Healthcare's (NSE:SAKAR) Earnings Growth?

Nov 22

Rendimenti per gli azionisti

	SAKAR	IN Pharmaceuticals	IN Mercato
7D	1.0%	2.0%	1.8%
1Y	-16.9%	58.6%	36.8%

Ritorno vs Industria: SAKAR underperformed the Indian Pharmaceuticals industry which returned 58.6% over the past year.

Rendimento vs Mercato: SAKAR underperformed the Indian Market which returned 36.8% over the past year.

Volatilità dei prezzi

Is SAKAR's price volatile compared to industry and market?
SAKAR volatility
SAKAR Average Weekly Movement	4.4%
Pharmaceuticals Industry Average Movement	6.3%
Market Average Movement	6.3%
10% most volatile stocks in IN Market	9.4%
10% least volatile stocks in IN Market	4.0%

Prezzo delle azioni stabile: SAKAR has not had significant price volatility in the past 3 months compared to the Indian market.

Volatilità nel tempo: SAKAR's weekly volatility (4%) has been stable over the past year.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
2004	325	Sanjay Shah	www.sakarhealthcare.com

Sakar Healthcare Limited ricerca, sviluppa, produce e commercializza prodotti farmaceutici in India. L'azienda fornisce orali liquidi, compresse di cefalosporine, capsule, sciroppi di polvere secca, iniezioni di polvere secca, liquidi iniettabili (SVP) in fiale, fiale e iniezioni liofilizzate, e dosaggi solidi orali. Il suo portafoglio prodotti comprende formulazioni in aree terapeutiche quali antiacido, antimalarico, anticoagulante, lassativo, antielmintico, broncodilatatore, anestetico, antidepressivo, sedativo, adrenergico, antinfettivo, diuretico, ossitocico, analgesico, antiemetico, antipsicotico, antimicotico, IPP, anticonvulsivante, antinfiammatorio, antistaminico e multi vitamine.

Sakar Healthcare Limited Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Sakar Healthcare con la sua capitalizzazione di mercato?
SAKAR statistiche fondamentali
Capitalizzazione di mercato	₹6.72b
Guadagni(TTM)	₹124.03m
Ricavi(TTM)	₹1.65b

54.2x

Rapporto P/E

4.1x

Rapporto P/S

SAKAR è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
SAKAR Conto economico (TTM)
Ricavi	₹1.65b
Costo del fatturato	₹911.33m
Profitto lordo	₹738.93m
Altre spese	₹614.90m
Guadagni	₹124.03m

Ultimi guadagni dichiarati

Sep 30, 2024

Prossima data di guadagno

n/a

Utile per azione (EPS)	5.70
Margine lordo	44.78%
Margine di profitto netto	7.52%
Rapporto debito/patrimonio netto	31.1%

Come si è comportato SAKAR nel lungo periodo?

Vedi performance storica e confronto

SAKAR Panoramica delle azioni

Premi

Analisi del rischio

Sakar Healthcare Limited Concorrenti

NSEI:INDSWFTLAB

₹6.9b

BSE:531146

₹6.8b

BSE:524075

₹8.0b

BSE:524212

₹7.6b

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Sakar Healthcare's (NSE:SAKAR) Anemic Earnings Might Be Worse Than You Think

Second quarter 2025 earnings released: EPS: ₹2.17 (vs ₹1.68 in 2Q 2024)

New minor risk - Shareholder dilution

First quarter 2025 earnings released: EPS: ₹1.10 (vs ₹1.46 in 1Q 2024)

Sakar Healthcare Limited, Annual General Meeting, Sep 21, 2024

Full year 2024 earnings released: EPS: ₹5.64 (vs ₹6.86 in FY 2023)

Recent updates

Sakar Healthcare's (NSE:SAKAR) Anemic Earnings Might Be Worse Than You Think

Second quarter 2025 earnings released: EPS: ₹2.17 (vs ₹1.68 in 2Q 2024)

New minor risk - Shareholder dilution

First quarter 2025 earnings released: EPS: ₹1.10 (vs ₹1.46 in 1Q 2024)

Sakar Healthcare Limited, Annual General Meeting, Sep 21, 2024

Full year 2024 earnings released: EPS: ₹5.64 (vs ₹6.86 in FY 2023)

Investor sentiment deteriorates as stock falls 15%

Third quarter 2024 earnings released: EPS: ₹0.98 (vs ₹2.16 in 3Q 2023)

Is Sakar Healthcare (NSE:SAKAR) A Risky Investment?

Second quarter 2024 earnings released: EPS: ₹1.68 (vs ₹1.01 in 2Q 2023)

Insufficient new directors

Investor sentiment improves as stock rises 20%

New major risk - Financial position

First quarter 2024 earnings released: EPS: ₹1.46 (vs ₹1.65 in 1Q 2023)

New major risk - Share price stability

Sakar Healthcare Limited announced that it expects to receive INR 599.999123 million in funding from Tata Investment Corporation Limited

Does Sakar Healthcare (NSE:SAKAR) Have A Healthy Balance Sheet?

Investor sentiment improves as stock rises 27%

Sakar Healthcare Limited, Annual General Meeting, Sep 21, 2023

Full year 2023 earnings released: EPS: ₹6.59 (vs ₹8.90 in FY 2022)

Is Sakar Healthcare (NSE:SAKAR) A Risky Investment?

Third quarter 2023 earnings released: EPS: ₹2.16 (vs ₹0.07 in 3Q 2022)

Here's Why Sakar Healthcare (NSE:SAKAR) Has Caught The Eye Of Investors

Investor sentiment improved over the past week

Is Sakar Healthcare (NSE:SAKAR) Using Too Much Debt?

Second quarter 2023 earnings released: EPS: ₹1.01 (vs ₹1.44 in 2Q 2022)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

First quarter 2023 earnings released: EPS: ₹1.65 (vs ₹1.80 in 1Q 2022)

Sakar Healthcare Limited, Annual General Meeting, Sep 20, 2022

Investor sentiment improved over the past week

Sakar Healthcare (NSE:SAKAR) Has A Somewhat Strained Balance Sheet

Full year 2022 earnings released: EPS: ₹8.73 (vs ₹7.09 in FY 2021)

Investor sentiment improved over the past week

Sakar Healthcare (NSE:SAKAR) Has A Somewhat Strained Balance Sheet

Investor sentiment improved over the past week

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS ₹1.44 (vs ₹3.04 in 2Q 2021)

Full year 2021 earnings released: EPS ₹7.09 (vs ₹6.43 in FY 2020)

Investor sentiment deteriorated over the past week

With EPS Growth And More, Sakar Healthcare (NSE:SAKAR) Is Interesting

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS ₹6.87 (vs ₹6.43 in FY 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Here's Why I Think Sakar Healthcare (NSE:SAKAR) Might Deserve Your Attention Today

Insider Buying: The Sakar Healthcare Limited (NSE:SAKAR) Chairman & MD Just Bought 7.1% More Shares

Has Sakar Healthcare Limited's (NSE:SAKAR) Impressive Stock Performance Got Anything to Do With Its Fundamentals?

Third quarter 2021 earnings released: EPS ₹1.20 (vs ₹1.48 in 3Q 2020)

Does Sakar Healthcare (NSE:SAKAR) Have A Healthy Balance Sheet?

Investor sentiment improved over the past week

New 90-day high: ₹107

Here's Why I Think Sakar Healthcare (NSE:SAKAR) Is An Interesting Stock

Market bids up stock over the past week

New 90-day high: ₹91.65

Should You Rely On Sakar Healthcare's (NSE:SAKAR) Earnings Growth?

First half earnings released

Market pulls back on stock over the past week